Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes
Authors' conclusions: There is no evidence to support the use of one particular form of insulin administration over another for pregnant women with diabetes. There are only a small number of trials appropriate for meta-analysis, a small number of women included and questionable generalisability of the trial population.

Pump technology has progressed since these trials were undertaken. Well-designed randomised trials are required to evaluate comparisons such as patch pumps against MDI and more conventional CSII against MDI. These trials should be adequately powered to assess the effect of interventions, and report the core set of outcomes used in Cochrane reviews of diabetes in pregnancy. Trials to assess the effects of pumps on birthweight and macrosomia rates are needed. It would be beneficial for future trials to undertake longer-term follow-up of participants and their infants, assess women's preferences, and conduct an economic evaluation.

Did you know that you now have free access to Cochrane Clinical Answers?
It provides brief evidence based summaries of information on popular clinical questions and links to the evidence from Cochrane Reviews on those questions. Here is a link to the Cochrane Clinical Answers on Diabetes, to give you an idea of what is available:
Cochrane Clinical Answers on Diabetes

• Liraglutide slightly reduces cardiovascular adverse events and mortality within 3-5 years in patients with type 2 diabetes (N Engl J Med 2016 Jul 28) 
• Insulin degludec/liraglutide may reduce HbA1c and hypoglycemic episodes compared to insulin glargine in patients with inadequately controlled type 2 diabetes receiving metformin (JAMA 2016 Mar 1)
• Liraglutide may improve glycemic control in patients with inadequately controlled type 2 diabetes receiving high-dose insulin therapy (JAMA Intern Med 2016 Jul)

Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK. Bain SC, Feher M, Russell-Jones D, Khunti K.

Assessment of response rates and yields for Two opportunistic Tools for Early detection of Non-diabetic hyperglycaemia and Diabetes (ATTEND). A randomised controlled trial and cost-effectiveness analysis. Khunti K, Gillies CL, Dallosso H, Brady EM, Gray LJ, Kilgallen G, Willis A, Zafar A, Davies MJ.

Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). Htike ZZ, Yates T, Brady EM, Webb D, Gray LJ, Swarbrick D, McCann GP, Khunti K, Davies MJ.

Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting. Davies MJ, Glah D, Chubb B, Konidaris G, McEwan P.

Engagement, Retention, and Progression to Type 2 Diabetes: A Retrospective Analysis of the Cluster-Randomised "Let's Prevent Diabetes" Trial. Gray LJ, Yates T, Troughton J, Khunti K, Davies MJ

The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Davies M, Chatterjee S, Khunti K.

Basal insulin peglispro vs insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial. Davies MJ, Russell-Jones D, Selam JL, Bailey TS, Kerényi Z, Luo J, Bue-Valleskey J, Iványi T, Hartman ML, Jacobson JG, Jacober SJ